PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
63.36
-1.55 (-2.39%)
Nov 12, 2026, 4:00 PM EST - Market closed
PTC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,156 | 1,731 | 806.78 | 937.82 | 698.8 | 538.59 | |
Revenue Growth | -35.05% | 114.51% | -13.97% | 34.20% | 29.75% | 41.45% |
Cost of Revenue | 517.87 | 502.26 | 591.88 | 732.05 | 696.17 | 573.01 |
Gross Profit | 637.69 | 1,228 | 214.9 | 205.77 | 2.63 | -34.42 |
Selling, General & Admin | 343.77 | 347.14 | 300.91 | 332.54 | 326 | 285.77 |
Amortization of Goodwill & Intangibles | 45.37 | 24.74 | 60.74 | 222.64 | 116.55 | 54.75 |
Operating Expenses | 389.13 | 371.89 | 361.65 | 555.18 | 442.55 | 340.52 |
Operating Income | 248.55 | 856.51 | -146.75 | -349.4 | -439.93 | -374.94 |
Interest Expense | -198.42 | -152.23 | -170.39 | -129.18 | -90.87 | -86.02 |
Currency Exchange Gain (Loss) | -5.1 | -23.1 | 1.1 | - | -31.3 | - |
Other Non Operating Income (Expenses) | -10.44 | -4.68 | 97.02 | 11.81 | -0.62 | -45.19 |
EBT Excluding Unusual Items | 34.6 | 676.5 | -219.02 | -466.78 | -562.71 | -506.15 |
Gain (Loss) on Sale of Investments | 3.82 | 9.69 | 11.73 | -1.68 | -17.29 | -12.69 |
Gain (Loss) on Sale of Assets | - | -0.1 | -4.4 | - | - | - |
Asset Writedown | -0.65 | -1.07 | -163.6 | -217.8 | -33.38 | - |
Other Unusual Items | -11.85 | 11.6 | 12.18 | -9.86 | 25.9 | 0.5 |
Pretax Income | -85.09 | 696.62 | -363.12 | -696.11 | -587.49 | -518.34 |
Income Tax Expense | 20.88 | 13.98 | 0.18 | -69.51 | -28.47 | 5.56 |
Net Income | -105.97 | 682.64 | -363.3 | -626.6 | -559.02 | -523.9 |
Net Income to Common | -105.97 | 682.64 | -363.3 | -626.6 | -559.02 | -523.9 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 83 | 80 | 77 | 75 | 72 | 70 |
Shares Outstanding (Diluted) | 83 | 88 | 77 | 75 | 72 | 70 |
Shares Change | -1.98% | 14.92% | 2.68% | 4.33% | 1.79% | 6.72% |
EPS (Basic) | -1.28 | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 |
EPS (Diluted) | -1.28 | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 2.07 | 702.34 | -114.19 | -186.86 | -388.67 | -279.55 |
Free Cash Flow Per Share | 0.03 | 7.95 | -1.49 | -2.50 | -5.42 | -3.97 |
Gross Margin | 55.18% | 70.98% | 26.64% | 21.94% | 0.38% | -6.39% |
Operating Margin | 21.51% | 49.49% | -18.19% | -37.26% | -62.95% | -69.62% |
Profit Margin | -9.17% | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% |
Free Cash Flow Margin | 0.18% | 40.58% | -14.15% | -19.92% | -55.62% | -51.90% |
EBITDA | 309.56 | 895.32 | -71.08 | -112.81 | -311.09 | -310.81 |
EBITDA Margin | 26.79% | 51.73% | -8.81% | -12.03% | -44.52% | -57.71% |
D&A For EBITDA | 61.01 | 38.82 | 75.66 | 236.59 | 128.84 | 64.13 |
EBIT | 248.55 | 856.51 | -146.75 | -349.4 | -439.93 | -374.94 |
EBIT Margin | 21.51% | 49.49% | -18.19% | -37.26% | -62.95% | -69.62% |
Effective Tax Rate | - | 2.01% | - | - | - | - |
Revenue as Reported | 1,156 | 1,731 | 806.78 | 937.82 | 698.8 | 538.59 |